Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.45 |
| ▸ | FURIN | P09958 | 8/20 | 0.43 |
| ▸ | NMT2 | O60551 | 1/20 | 0.41 |
| ▸ | NMT1 | P30419 | 1/20 | 0.41 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30964325 | 0.95 | FURIN (0.44) | SLC15A2FURINNMT2NMT1 | |
| SCHEMBL30964332 | 0.91 | SLC15A2 (0.47) | SLC15A2FURIN | |
| SCHEMBL30964326 | 0.89 | GRIN2D (0.46) | FURIN | |
| SCHEMBL30964333 | 0.89 | SLC15A2 (0.51) | SLC15A2FURINNMT2NMT1SLC6A5 | |
| SCHEMBL29826021 | 0.88 | SLC6A5 (0.45) | SLC15A2FURINNMT2NMT1SLC6A5 | |
| SCHEMBL30902091 | 0.87 | NMT2 (0.42) | SLC15A2FURINNMT2NMT1SLC6A5 | |
| SCHEMBL31202999 | 0.87 | SLC15A2 (0.45) | SLC15A2FURINSLC6A5 | |
| SCHEMBL29706336 | 0.86 | SLC15A2 (0.50) | SLC15A2NMT2NMT1SLC6A5 | |
| SCHEMBL30964328 | 0.86 | GRIN2D (0.43) | FURIN | |
| SCHEMBL30964329 | 0.83 | OPRD1 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240218017-A1 | PEPTIDE AMPHIPHILES WITH MODIFIED DEGRADING SEQUENCES AND METHODS OF USE THEREOF | Endomimetics LLC | 2024-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240218017-A1 | PEPTIDE AMPHIPHILES WITH MODIFIED DEGRADING SEQUENCES AND METHODS OF USE THEREOF | ABHD16A, LIPG, POLQ | SLC15A2 3641/4885FURIN 1925/4885NMT2 3728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.